MAI Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

MAI Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300	Closed	-$912	–	3619
2024 Q4	$912	Buy	+300	New	+$1.31K	﹤0.01%	3211
2023 Q2	–	Sell	-11,788	Closed	-$380K	–	1132
2023 Q1	$380K	Buy	11,788 +79	+0.7%	+$2.46K	0.01%	722
2022 Q4	$216K	Hold	11,709	–	–	﹤0.01%	886
2022 Q3	$316K	Sell	11,709 -89	-0.8%	-$1.8K	0.01%	682
2022 Q2	$163K	Hold	11,798	–	–	﹤0.01%	813
2022 Q1	$230K	Hold	11,798	–	–	﹤0.01%	786
2021 Q4	$193K	Buy	+11,798	New	+$197K	﹤0.01%	835

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MAI Capital Management's RVNC Position: Q1 2025 in Review

MAI Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 300 shares — an estimated $912 sold.

MAI Capital Management first reported a position in RVNC in Q4 2021 and held it in 7 quarters. The position peaked at $380K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

MAI Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
MAI Capital Management sold 300 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $912.
MAI Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 7 quarters.
MAI Capital Management's Revance Therapeutics, Inc. position peaked at $380K in Q1 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on MAI Capital Management's 13F filing for Q1 2025, filed 15 May 2025.